Status:
COMPLETED
Routine Lymphadenectomy for Intrahepatic Cholangiocarcinoma
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University
Collaborating Sponsors:
Ningxia Medical University
Nanchang University
Conditions:
Intrahepatic Cholangiocarcinoma
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The role of routine lymphadenectomy (LND) in the surgical treatment of intrahepatic cholangiocarcinoma (ICC) remains controversial. The investigators' multi-institutional retrospective study have show...
Detailed Description
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer and its incidence is increasing worldwide.Resection of the primary ICC tumor site within the liver represents the b...
Eligibility Criteria
Inclusion
- Patients diagnosed with intrahepatic cholangiocarcinoma by imaging or biopsy
- The tumor is limited in the liver with no distant metastasis, and the primary disease is resectable
- Preoperative imaging (e.g. CT, MRI, PET-CT, etc.) and intraoperative exploration found no nodal swelling or enlargement
Exclusion
- The primary disease is unresectable with or without distant metastasis
- The liver function or general condition of patients does not permit surgery
- Preoperative imaging (e.g. CT, MRI, PET-CT, etc.) and intraoperative exploration found obvious nodal swelling or enlargement, which indicates lymphadenectomy should be performed
- Patients aged below 18 or older than 65 would be excluded
- Pregnant women would not be enrolled
Key Trial Info
Start Date :
January 10 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT03796819
Start Date
January 10 2019
End Date
December 1 2021
Last Update
December 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China, 710061